Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients

Jichi Medical University

Status and phase

Completed

Phase 4

Conditions

Chronic Kidney Disease

Hypertension

Treatments

Drug: Aliskiren

Study type

Interventional

Funder types

Other

Identifiers

NCT01284114

JMU-N1

Details and patient eligibility

About

The purpose of this study is to determine whether aliskiren is effective in the treatment of blood pressure, hear function, renal function in elderly hypertensive chronic kidney disease (CKD) patients.

Full description

Chronic kidney disease (CKD) was reported to be affecting 11% of the all population. This number is much higher in the elderly population and may be as high as 30%. CKD is an independent risk factor of cardiovascular disease (CVD). This is called "Cardio-renal Continuum". The renin-angiotensin-aldosterone system (RAS) plays pivotal roles in both cardiovascular and renal functions.

The increased oxidative stress by activated RAS on vascular endothelium is one of important factor to development of Cardio-renal Continuum. The blockade of RAS by angiotensin I converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) has been reported to ameliorate the renal disease and CVD; however,they do not completely suppress RAS, leading to a reactive rise in plasma renin activity (PRA). Aliskiren, an oral direct renin inhibitor, is effective against essential hypertension by reducing PRA, resulting in more complete suppression of RAS; however, little is known about the effects of aliskiren on heart and kidney functions in elderly hypertensive CKD patients. In this study, we assessed the efficacy of aliskiren on heart and kidney functions in elderly hypertensive CKD patients.

Enrollment

23 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of Chronic kidney disease
Clinical diagnosis of Hypertension (Blood pressure >=140/90mmHg)
Elderly people(>=65 years old)

Exclusion criteria

The patients who are already taking aliskiren
The patients who are receiving hemodialysis or peritoneal dialysis
The patients who are taking cyclosporin
The patients who have hyperkalemia(>=5.5mEq/ml)
Severe heart failure (>=NYHA class III)
Insulin dependent diabetic mellitus or poor controlled insulin independent diabetic mellitus (>=HbA1c 9.0&)
Severe liver dysfunction (five folds increased AST or ALT than standard values)